arrow
A

Alfredo Falcone

University of North Carolina Chapel Hill
H指数:89
被引数:4.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Trial Data Review of the Combination FTD/TPI plus Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer

FTD/TPI联合贝伐单抗治疗不可切除转移性结直肠癌的临床试验数据回顾

2024-09-260
OAAI
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study
2023-03-0117
PRE
Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials
2023-03-011
OAAI
Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study

氟尿嘧啶-替比拉西联合贝伐单抗与卡培他滨联合贝伐单抗一线治疗不适合强化治疗的转移性结直肠癌患者 (SOLSTICE): 一项随机、开放标签的3期研究

2023-02-0120
PRE
Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials
2022-09-014
OAAI
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients
2022-03-215
OAAI
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients

PARERE试验的基本原理和研究设计: 在RAS和BRAF野生型化疗难治性转移性结直肠癌患者中,帕尼单抗再治疗后瑞戈非尼与反向序列的随机II期研究

2021-12-0116
PRE
Detailing the ultrastructure's increase of prion protein in pancreatic adenocarcinoma

胰腺腺癌中朊蛋白增加的超微结构细节

2021-11-142
OAAI
Original Research Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study

转移性结直肠癌的肿瘤突变负荷、微卫星不稳定性和可行改变的原始研究: TRIBE2研究的下一代测序结果

2021-09-0115
PRE
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications

结直肠癌的同源重组缺陷改变: 临床,分子和预后意义

2021-09-0139
OA
FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO
2021-09-0126
OAAI
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study

探索FOLFOXIRI/bevacizumab在BRAF突变的转移性结直肠癌患者中获益的临床和基因表达标志物: TRIBE2研究的亚组分析

2021-08-015
PRE
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies

CEA升高是转移性结直肠癌患者一线诱导治疗后疾病进展的标志。部落和部落2研究的汇总分析

2021-07-1215
OAAI